OCUL
Ocular Therapeutix, Inc.$8.72+0.03 (+0.29%)Prev Close$8.70·MCap$1.91B·P/E—·Vol1.52M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
27
$3.43M
◆
Net Activity
Net Seller
$3.43M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Ocular Therapeutix, Inc. (OCUL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 27 insider sales totaling $3.43M. The most recent insider transaction was by Waheed Nadia (officer: Chief Medical Officer), who sold $122.6K worth of shares on Jun 5, 2026. Ocular Therapeutix, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.91B.
OCUL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Waheed Nadia | officer: Chief Medical Officer | Sell | 14,828 | $8.27 | $122.6K | 300,079 |
| May 28, 2026 | Heier Jeffrey S. | officer: Chief Scientific Officer | Sell | 3,018 | $8.20 | $24.7K | 320,350 |
| May 28, 2026 | Nayak Sanjay | officer: Chief Strategy Officer | Sell | 1,858 | $8.20 | $15.2K | 328,795 |
| May 28, 2026 | Kaiser Peter | officer: Chief Development Officer | Sell | 2,967 | $8.20 | $24.3K | 266,141 |
| May 28, 2026 | Dugel Pravin | director, officer: See Remarks | Sell | 21,156 | $8.20 | $173.5K | 2,597,170 |
| Feb 25, 2026 | Dugel Pravin | director, officer: See Remarks | Sell | 20,056 | $8.28 | $166.1K | 3,013,022 |
| Feb 25, 2026 | Heier Jeffrey S. | officer: Chief Scientific Officer | Sell | 3,057 | $8.28 | $25.3K | 323,368 |
| Feb 25, 2026 | Kaiser Peter | officer: Chief Development Officer | Sell | 2,810 | $8.28 | $23.3K | 269,108 |
| Feb 25, 2026 | Nayak Sanjay | officer: Chief Strategy Officer | Sell | 1,759 | $8.28 | $14.6K | 330,653 |
| Feb 12, 2026 | Dugel Pravin | See Remarks | Sell | 124,882 | $9.04 | $1.13M | 0 |
| Feb 12, 2026 | Nayak Sanjay | Chief Strategy Officer | Sell | 10,348 | $9.04 | $93.5K | 0 |
| Feb 12, 2026 | Notman Donald | Chief Operating Officer | Sell | 11,446 | $9.04 | $103.5K | 0 |
| Feb 12, 2026 | Waheed Nadia | Chief Medical Officer | Sell | 7,863 | $9.04 | $71.1K | 0 |
| Feb 4, 2026 | Notman Donald | officer: Chief Operating Officer | Sell | 11,490 | $8.82 | $101.4K | 383,837 |
| Nov 26, 2025 | Dugel Pravin | See Remarks | Sell | 19,530 | $12.04 | $235.1K | 3,157,960 |
| Nov 26, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,469 | $12.04 | $41.8K | 245,940 |
| Nov 26, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,007 | $12.02 | $36.1K | 191,433 |
| Nov 26, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,878 | $12.04 | $22.6K | 277,860 |
| Nov 7, 2025 | Saroj Namrata | Chief Business Officer | Sell | 25,865 | $10.74 | $277.8K | 174,135 |
| Oct 10, 2025 | Anderman Todd | Chief Legal Officer | Sell | 11,132 | $12.34 | $137.4K | 87,568 |
| Oct 6, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 10,502 | $11.04 | $115.9K | 249,409 |
| Oct 6, 2025 | Kaiser Peter | Chief Development Officer | Sell | 9,653 | $11.03 | $106.5K | 194,440 |
| Sep 4, 2025 | Notman Donald | See Remarks | Sell | 1,066 | $12.43 | $13.3K | 308,807 |
| Aug 27, 2025 | Dugel Pravin | See Remarks | Sell | 21,494 | $12.04 | $258.8K | 3,227,244 |
| Aug 27, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,063 | $12.04 | $36.9K | 259,911 |
| Aug 27, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,011 | $12.04 | $36.3K | 204,093 |
| Aug 27, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,885 | $12.04 | $22.7K | 279,738 |
| Jun 3, 2025 | Waheed Nadia | Chief Medical Officer | Sell | 13,861 | $8.05 | $111.6K | 206,805 |
| May 27, 2025 | Dugel Pravin | See Remarks | Sell | 21,219 | $7.18 | $152.4K | 3,499,099 |
| May 27, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,024 | $7.18 | $21.7K | 262,974 |
| May 27, 2025 | Kaiser Peter | Chief Development Officer | Sell | 2,974 | $7.17 | $21.3K | 207,104 |
| May 27, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,862 | $7.17 | $13.4K | 281,623 |
| May 12, 2025 | LINDSTROM RICHARD L MD | Director | Buy | 10,000 | $6.96 | $69.6K | 172,704 |
| Feb 26, 2025 | Dugel Pravin | See Remarks | Sell | 21,475 | $6.87 | $147.5K | 3,520,318 |
| Feb 26, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,061 | $6.87 | $21.0K | 265,998 |
| Feb 26, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,009 | $6.87 | $20.7K | 210,078 |
| Feb 26, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,895 | $6.84 | $13.0K | 283,485 |
| Feb 4, 2025 | Notman Donald | See Remarks | Sell | 17,420 | $7.82 | $136.2K | 204,563 |
| Nov 27, 2024 | Dugel Pravin | See Remarks | Sell | 20,680 | $9.01 | $186.3K | 791,793 |
| Nov 27, 2024 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 2,948 | $9.01 | $26.6K | 269,059 |
| Nov 27, 2024 | Kaiser Peter | Chief Development Officer | Sell | 2,897 | $9.01 | $26.1K | 213,087 |
| Nov 27, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,814 | $9.00 | $16.3K | 174,380 |
| Aug 27, 2024 | Dugel Pravin | See Remarks | Sell | 20,880 | $9.02 | $188.3K | 812,473 |
| Aug 27, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,832 | $9.02 | $16.5K | 176,194 |
| May 28, 2024 | Dugel Pravin | See Remarks | Sell | 21,626 | $5.79 | $125.2K | 833,353 |
| May 28, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 2,274 | $5.84 | $13.3K | 178,026 |
| Feb 27, 2024 | SUMMER ROAD LLC | Buy | 930,851 | $7.52 | $7.00M | 8,591,401 | |
| Feb 6, 2024 | Mattessich Antony C. | President and CEO | Sell | 19,642 | $4.86 | $95.5K | 588,701 |
| Feb 6, 2024 | Notman Donald | Chief Financial Officer | Sell | 6,212 | $4.86 | $30.2K | 195,356 |
| Feb 6, 2024 | Ozden Rabia Gurses | Chief Medical Officer | Sell | 6,346 | $4.86 | $30.8K | 153,054 |
Showing 1–50 of 78
1 / 2
OCUL Insider Buying Activity
The following table shows recent insider purchases of Ocular Therapeutix, Inc. (OCUL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 12, 2025 | LINDSTROM RICHARD L MD | Director | Buy | 10,000 | $6.96 | $69.6K | 172,704 |
| Feb 27, 2024 | SUMMER ROAD LLC | Buy | 930,851 | $7.52 | $7.00M | 8,591,401 |
OCUL Insider Selling Activity
The following table shows recent insider sales of Ocular Therapeutix, Inc. (OCUL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Waheed Nadia | officer: Chief Medical Officer | Sell | 14,828 | $8.27 | $122.6K | 300,079 |
| May 28, 2026 | Heier Jeffrey S. | officer: Chief Scientific Officer | Sell | 3,018 | $8.20 | $24.7K | 320,350 |
| May 28, 2026 | Nayak Sanjay | officer: Chief Strategy Officer | Sell | 1,858 | $8.20 | $15.2K | 328,795 |
| May 28, 2026 | Kaiser Peter | officer: Chief Development Officer | Sell | 2,967 | $8.20 | $24.3K | 266,141 |
| May 28, 2026 | Dugel Pravin | director, officer: See Remarks | Sell | 21,156 | $8.20 | $173.5K | 2,597,170 |
| Feb 25, 2026 | Dugel Pravin | director, officer: See Remarks | Sell | 20,056 | $8.28 | $166.1K | 3,013,022 |
| Feb 25, 2026 | Heier Jeffrey S. | officer: Chief Scientific Officer | Sell | 3,057 | $8.28 | $25.3K | 323,368 |
| Feb 25, 2026 | Kaiser Peter | officer: Chief Development Officer | Sell | 2,810 | $8.28 | $23.3K | 269,108 |
| Feb 25, 2026 | Nayak Sanjay | officer: Chief Strategy Officer | Sell | 1,759 | $8.28 | $14.6K | 330,653 |
| Feb 12, 2026 | Dugel Pravin | See Remarks | Sell | 124,882 | $9.04 | $1.13M | 0 |
| Feb 12, 2026 | Nayak Sanjay | Chief Strategy Officer | Sell | 10,348 | $9.04 | $93.5K | 0 |
| Feb 12, 2026 | Notman Donald | Chief Operating Officer | Sell | 11,446 | $9.04 | $103.5K | 0 |
| Feb 12, 2026 | Waheed Nadia | Chief Medical Officer | Sell | 7,863 | $9.04 | $71.1K | 0 |
| Feb 4, 2026 | Notman Donald | officer: Chief Operating Officer | Sell | 11,490 | $8.82 | $101.4K | 383,837 |
| Nov 26, 2025 | Dugel Pravin | See Remarks | Sell | 19,530 | $12.04 | $235.1K | 3,157,960 |
| Nov 26, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,469 | $12.04 | $41.8K | 245,940 |
| Nov 26, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,007 | $12.02 | $36.1K | 191,433 |
| Nov 26, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,878 | $12.04 | $22.6K | 277,860 |
| Nov 7, 2025 | Saroj Namrata | Chief Business Officer | Sell | 25,865 | $10.74 | $277.8K | 174,135 |
| Oct 10, 2025 | Anderman Todd | Chief Legal Officer | Sell | 11,132 | $12.34 | $137.4K | 87,568 |
| Oct 6, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 10,502 | $11.04 | $115.9K | 249,409 |
| Oct 6, 2025 | Kaiser Peter | Chief Development Officer | Sell | 9,653 | $11.03 | $106.5K | 194,440 |
| Sep 4, 2025 | Notman Donald | See Remarks | Sell | 1,066 | $12.43 | $13.3K | 308,807 |
| Aug 27, 2025 | Dugel Pravin | See Remarks | Sell | 21,494 | $12.04 | $258.8K | 3,227,244 |
| Aug 27, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,063 | $12.04 | $36.9K | 259,911 |
| Aug 27, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,011 | $12.04 | $36.3K | 204,093 |
| Aug 27, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,885 | $12.04 | $22.7K | 279,738 |
| Jun 3, 2025 | Waheed Nadia | Chief Medical Officer | Sell | 13,861 | $8.05 | $111.6K | 206,805 |
| May 27, 2025 | Dugel Pravin | See Remarks | Sell | 21,219 | $7.18 | $152.4K | 3,499,099 |
| May 27, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,024 | $7.18 | $21.7K | 262,974 |
| May 27, 2025 | Kaiser Peter | Chief Development Officer | Sell | 2,974 | $7.17 | $21.3K | 207,104 |
| May 27, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,862 | $7.17 | $13.4K | 281,623 |
| Feb 26, 2025 | Dugel Pravin | See Remarks | Sell | 21,475 | $6.87 | $147.5K | 3,520,318 |
| Feb 26, 2025 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 3,061 | $6.87 | $21.0K | 265,998 |
| Feb 26, 2025 | Kaiser Peter | Chief Development Officer | Sell | 3,009 | $6.87 | $20.7K | 210,078 |
| Feb 26, 2025 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,895 | $6.84 | $13.0K | 283,485 |
| Feb 4, 2025 | Notman Donald | See Remarks | Sell | 17,420 | $7.82 | $136.2K | 204,563 |
| Nov 27, 2024 | Dugel Pravin | See Remarks | Sell | 20,680 | $9.01 | $186.3K | 791,793 |
| Nov 27, 2024 | Heier Jeffrey S. | Chief Scientific Officer | Sell | 2,948 | $9.01 | $26.6K | 269,059 |
| Nov 27, 2024 | Kaiser Peter | Chief Development Officer | Sell | 2,897 | $9.01 | $26.1K | 213,087 |
| Nov 27, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,814 | $9.00 | $16.3K | 174,380 |
| Aug 27, 2024 | Dugel Pravin | See Remarks | Sell | 20,880 | $9.02 | $188.3K | 812,473 |
| Aug 27, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 1,832 | $9.02 | $16.5K | 176,194 |
| May 28, 2024 | Dugel Pravin | See Remarks | Sell | 21,626 | $5.79 | $125.2K | 833,353 |
| May 28, 2024 | Nayak Sanjay | Chief Strategy Officer | Sell | 2,274 | $5.84 | $13.3K | 178,026 |
| Feb 6, 2024 | Mattessich Antony C. | President and CEO | Sell | 19,642 | $4.86 | $95.5K | 588,701 |
| Feb 6, 2024 | Notman Donald | Chief Financial Officer | Sell | 6,212 | $4.86 | $30.2K | 195,356 |
| Feb 6, 2024 | Ozden Rabia Gurses | Chief Medical Officer | Sell | 6,346 | $4.86 | $30.8K | 153,054 |
OCUL Insiders
Heier Jeffrey S.
officer: Chief Scientific Officer
Bought $45.8KSold $313.9K
9 tradesLast: May 28, 2026
Similar Stocks to OCUL
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B